Why Teva’s Price Target Just Got Nudged Higher Teva Pharmaceutical Industries just saw its fair value estimate move from ...

Teva Pharmaceutical Industries Ltd ADR has reached a significant milestone, with its stock hitting a 52-week high at $32.02. This achievement marks a notable recovery and growth trajectory for the ...

Teva Pharmaceutical Industries Limited’s TEVA stock has declined 10% in a month despite strong third-quarter results announced earlier this month. The company beat estimates for earnings as well as ...

Teva Pharmaceutical Industries recently reported third-quarter 2025 earnings that exceeded analysts’ expectations, advanced ...

Teva Pharmaceutical Industries Limited’s TEVA stock has been trading above its 50-day and 200-day simple moving averages (SMAs) since the end of October. It achieved the golden cross in mid-September.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best affordable healthcare stocks to buy now. Teva ...

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) and Biolojic Design Ltd announced that Teva initiated IND-enabling studies with BD9, a dual-specific multibody targeting both TSLP (Thymic stromal ...

The person behind the modification was JPMorgan Chase analyst Chris Schott, who pushed up his Teva stock recommendation one notch from neutral to overweight (read: buy). He also bumped his price ...

Teva Pharmaceutical stock has rebounded from lows, driven by debt reduction, halted price deflation in generics, and new product launches, making it a strong buy. Teva's innovative branded drugs and ...

BD9 blocks both TSLP and IL-13, two major drivers of TH2 inflammation. Biolojic to receive milestone payments tied to BD9 development progress. Special Access: Get Market Moving News Up to 15 Minutes ...